The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Tipifarnib for the Treatment of Older Patients With AML

Harry Erba, MD, PhD
Published Online:3:28 PM, Wed March 12, 2014
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with acute myeloid leukemia (AML).

Clinical Pearls

  • Tipifarnib is a farnesyltransferase inhibitor
  • Tipifarnib was studied in older, untreated patients with AML in a large, randomized phase II study
  • This study accrued 348 patients to four different treatment arms in 15 months
  • At the start of the study, there was little data showing that tipifarnib was effective
  • This study recapitulated prior work, which showed a 15-20% response rate with tipifarnib
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.